It's one of Australia's biggest killers — and there's a new tool to tackle it
He said that makes them: "very, very hard to treat — and making survivability much lower than some of the other cancers where we're seeing survivability increase quite dramatically."
LISTEN TO
SBS News
05/07/2025 12:37 English Anita Dessaix, chair of the Cancer Council's public health committee, said lung cancer mortality is especially a problem in some migrant communities and definitely so for Indigenous Australians, whose rates of diagnosis have been rising.
"There are particular parts of the population that experience currently worser outcomes, and that does include people who are living in rural and remote areas in Australia," Dessaix said. "Those who potentially don't have English as their first language — so culturally and linguistically diverse communities — and also those who are Aboriginal and Torres Strait Islander people."
Who can access the new lung cancer screening program? The Australian government has funded a national early screening program it hopes will bring down those numbers. Scans to detect lung issues normally cost hundreds of dollars, but Butler said that they will now cost nothing for patients deemed to be at high risk of lung cancer.
That includes people who are:
Between 50 and 70 years old
Show no signs or symptoms of lung cancer
Have a history of at least 30 pack-years of cigarette smoking, or are still smoking, or have quit in the past 10 years Butler said the program will entitle high risk patients "to a CT scan every two years, designed to pick up any early evidence of lung cancer and allow them then to be treated hopefully very, very successfully". He said people in regional communities would also be able to access the program later this year, with trucks equipped with mobile CT scan technology set to be rolled out in these areas. The international evidence for these types of screening programs is promising. Butler it suggests up to 70 percent of lung cancers are detected at early stages by low-dose CT scans, and deaths are subsequently reduced by 20 percent. Accordingly the CEO of the Lung Foundation Australia, Mark Brooke, hopes this program — the first new national cancer screening program in 20 years — will be a game changer. "We will be one of the first countries in the world to have a national lung cancer screening program that will look across Australia," Brooke said. "And particularly because it's been co-designed with Aboriginal and Torres Strait Islander people, will support those people who have often been forgotten."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
30 minutes ago
- News.com.au
Major crackdown on medicinal cannabis, doctor writes 17k scripts
Some practitioners have issued more than 10,000 medicinal cannabis prescriptions in just six months, it can be revealed as Australia's health watchdog announces a major crackdown. Authorities have become concerned at 'poor practice' in the burgeoning industry, saying it has led to underage patients receiving scripts and reports of medicinal cannabis-induced psychosis. The Australian Health Practitioner Regulation Agency (Ahpra) and National Boards on Wednesday announced the first official guidelines for prescribing the drug. 'We don't prescribe opioids to every patient who asks for them, and medicinal cannabis is no different,' Medical Board of Australia Chair Dr Susan O'Dwyer said. 'Patient demand is no indicator of clinical need.' The regulators said a lax system had led to fears of profits 'over patient safety', citing reports of 'serious adverse outcomes such as psychotic episodes' for patients whose medical history was not properly considered. One practitioner is believed to have written 17,000 scripts in half a year, while seven others issued more than 10,000 each. Some consultations are lasting 'a few seconds', according to Aphra, and cannabis was being prescribed simply because patients were requesting it. The new guidelines include thorough assessment of patients, taking their medical history into account, creating management plans and continuity of care, maintaining medical records and offering different treatment options. Ahpra chief executive Justin Untersteiner warned practitioners of the inherent conflict of interest for working in an organisation that only prescribes and dispenses a single medicine. 'Some business models that have emerged in this area rely on prescribing a single product or class of drug and use online questionnaires that coach patients to say 'the right thing' to justify prescribing medicinal cannabis,' Mr Untersteiner said. 'This raises the very real concern that some practitioners may be putting profits over patient welfare.' Ahpra has taken action against 57 medical practitioners, pharmacists and nurses over medicinal cannabis prescribing practices and is investigating 60 more. Mr Untersteiner added Ahpra 'will investigate practitioners with high rates of prescribing any scheduled medicine, including medicinal cannabis, even if we have not received a complaint'. GPs and qualified nurses have been able to prescribe medicinal cannabis for patients under a legal access scheme since 2016. Under the laws they must only make the prescription after identifying a therapeutic need and undertaking a thorough patient assessment. Data from the Penington Institute showed in November that Australians spent $400 million on medicinal cannabis in the first six months of 2024. That was up on the $234 million for the whole of 2022. Ahpra estimated last February that the number of unregistered users of medicinal cannabis products had 'spiralled' from 18,000 in 2019 to more than one million by January 2024. Wayne Hall, a professor at the National Centre for Research on Youth Substance Use Research at the University of Queensland, told The Guardian last year he expected Australia's market to follow a trajectory seen in Canada and the US. 'When you create a medical cannabis program … the pressure is often brought to bear to expand it so it merges into a de facto legal cannabis market for adults,' Prof Hall said. In a statement the Therapeutic Goods Administration welcomed the new guidelines, saying it was working closely with regulators to ensure safe prescription of medicines.
ABC News
an hour ago
- ABC News
Concern over medicinal cannabis prescribing
Isabella Higgins: The medical regulator is releasing new guidance for practitioners about the prescribing of medicinal cannabis. It comes after the Australian Health Practitioner Regulation Agency found evidence that poor practices and surging patient demand is leading to significant patient harm. I spoke with National Health Reporter, Elise Worthington, a short time ago. Elise, first of all, what sort of problems has APHRA discovered with the prescribing and use of medicinal cannabis? Elise Worthington: Well, the number of Australians being prescribed medicinal cannabis has absolutely exploded in the past few years. And that's come about as medicinal cannabis telehealth companies have popped up, offering a really convenient, quick way for patients to get prescriptions after short online consultations. But the regulator is concerned that there's been a lack of due diligence by doctors who aren't taking proper medical histories and might be influenced by the companies they work for, which are also selling the products they're prescribing. So we've previously reported that APHRA has actually discovered more than half a dozen doctors have written over 10,000 medicinal cannabis scripts in a six month period. And they found one who'd written more than 17,000. So that equals about one every four minutes in a working day, which has really raised questions for them about how thoroughly patients are being screened. Now APHRA CEO, Justin Untersteiner said that has led to concerns about patient safety. Justin Untersteiner: We are concerned by reports of patients presenting to emergency departments with medicinal cannabis induced psychosis. We're also seeing evidence of over-servicing of patients, as well as ethical grey areas around cannabis only retail facilities. Some business models that have emerged in this area rely on prescribing a single product or a class of drug. And they use online questionnaires that we feel coach patients to say the right thing to justify prescribing medicinal cannabis. Isabella Higgins: That's APHRA's CEO, Justin Untersteiner. And Elise, has APHRA taken any action so far? Elise Worthington: Yes, so APHRA is working with other agencies like the Therapeutic Goods Administration. Now doctors have to report to the TGA, their medicinal cannabis prescriptions that they write. So APHRA is looking at the data and they have said today that they've taken action against 57 prescribers and they're now investigating another 60 doctors, pharmacists and nurse practitioners who can also prescribe medicinal cannabis. And they're really putting doctors working at these telehealth companies on notice that even if there's not a complaint from a patient, they will be asking questions about how they're writing so many scripts, checking their notes and medical records to ensure that patients are actually being properly assessed. Isabella Higgins: And what exactly is in this new guidance for practitioners in how they prescribe and what does APHRA hope they achieve? Elise Worthington: There's actually really strong evidence taking a step back that medicinal cannabis can really help with things like treating childhood epilepsy, muscle spasms, pain associated with multiple sclerosis and cancer, as well as chemotherapy-induced nausea and vomiting. But interestingly, that is not the main conditions that it's being prescribed for in Australia. So we can see that it's mainly being prescribed for things like insomnia, anxiety and chronic pain. So the guidance is quite interesting in that it really clearly states that medicinal cannabis should never be prescribed as a first-line treatment because it's an unapproved therapy for most conditions, excluding some of those ones I mentioned earlier. But that also means that it's not checked for safety, quality or efficacy by the TGA. And the guidelines state that there's not good evidence showing that it works for a lot of other conditions and patients need to be explicitly informed of that when they're being prescribed it. Isabella Higgins: Elise Worthington reporting.
News.com.au
an hour ago
- News.com.au
‘Screw over': Truth about Donald Trump's plan to impose crippling 200 per cent tariffs on Australian pharmaceuticals
US President Donald Trump's plan to drop a 200 per cent tariff bomb on Australian pharmaceuticals is set to 'screw over' the sickest and most vulnerable in the United States suffering rare and life-threatening conditions including burns patients. As the Albanese Government scrambles to secure more information about the US government's latest plans, Australian officials are sounding the alarm given that pharmaceutical exports are worth over $2 billion a year. All plasma products collected in Australia stay here and are not exported to the US. Instead, the export issue relates to vaccines and blood products collected overseas and sent to Australia for processing before being returned to the US. President Donald Trump has threatened to introduce 200 per cent tariffs on pharmaceuticals – one of Australia's biggest exports to the US. Speaking to the media before a cabinet meeting, the President suggested the 'very, very high' levies on pharmaceuticals would not go into effect immediately, saying he would give drug manufacturers 'about a year, year and a half' to respond and relocate their operations to the US. 'They're going to be tariffs at a very high rate, like 200 per cent,' Mr Trump told reporters. 'We'll give them a certain period of time to get their act together,' he added, seemingly referring to drug manufacturers bringing back manufacturing into the US. Australia is subject to a 10 per cent 'baseline' tariff, which was the minimum rate imposed on all US trading partners by Mr Trump earlier this year. Australia's plasma exports to the US One of the biggest sections of the market includes blood products such as plasma products including exports linked to CSL Plasma which collects blood plasma in the United States. In 2023, Australia exported $1.42 billion of vaccines, blood, antisera, toxins and cultures, making it the 20th largest exporter of 208 in the world. Blood collection is a commercial operation in the United States, with plasma donors typically paid for their blood. CSL Plasma operates one of the world's largest and most sophisticated plasma collection networks, with nearly 350 plasma collection centers in the US and elsewhere. The blood products are mostly processed in the US but some are sent back to Australia to manufacture therapies for a variety of rare and life-threatening conditions. These conditions include primary immunodeficiencies, bleeding disorders like hemophilia, neurological disorders, and critical care needs like those arising from trauma or burns. One Australian official predicted that demand for the products would continue but the tariffs would 'screw over' patients relying on the notorious US healthcare system. Vulnerable patients will be hit with cost increases because the tariffs are paid by importers, not Australian exporters. CSL has a factory in Melbourne Biotech giant CSL has a plasma fractionation facility in Broadmeadows in Melbourne. The impact of the threatened tariffs relates to the commercial arm of CSL. which uses US blood products which are sourced in America and then processed in Australia before being sent back. 'Plasma manufacturing is a really fragile supply chain because it starts in a human vein,'' an industry source said. 'It's not a tap that you can turn on or off. You need people to vote with their feet to go into a facility that is enabled to collect plasma, and the demand for plasma products is growing globally each year.' 'Tariffs on pharmaceuticals impact the end user.' Treasurer Jim Chalmers 'very concerned' The Treasurer said on Wednesday that Washington's latest announcement was 'very concerning'. 'These are obviously very concerning developments,' Mr Chalmers told the ABC, adding that it had 'been a feature of recent months that we've had these sorts of announcements out of DC'. 'It's still early days. Obviously, we'll make a more detailed assessment of what's come out of the US in the usual way.' 'Our pharmaceuticals industry is much more exposed to the US market, and that's why we're seeking - urgently seeking - some more detail on what's been announced. 'But I want to make it really clear once again … our Pharmaceutical Benefit Scheme is not something that we're willing to trade away or do deals on – that won't change.' 'We've made it very clear that we think these tariffs are bad for the US, bad for Australia and bad for the global economy.' Mr Chalmers said one of the things the Albanese Government was 'most concerned' about was in addition to the direct impact on Australian workers and industries caused by this tariff, was the 'impact on global demand more broadly'. 'That's why we've been … at every opportunity, making the case that these tariffs are unjustified, they should be removed in line with our free trade agreement,' he said. The Prime Minister has described the taxes on Australian exports to the US as an 'act of economic self-harm'. 'Tariffs are a penalty on the country that is imposing them, because what they require is for goods to be purchased with a tax on top, and the US has made that decision,' the Prime Minister said. How plasma exports are used to help patients CSL Behring uses a process called plasma fractionation to separate the collected plasma into different components, such as immunoglobulins, coagulation factors, and other proteins. One example is helping people with bleeding disorders, with doctors utilising coagulation factors that are used to help patients with hemophilia and other bleeding disorders. Plasma-derived products are also used in emergency situations like severe trauma, burns, and shock to replace lost blood volume and proteins. For now, Australian officials concerned about the impact on blood product exports don't have full clarity on how it will impact the supply chain process.
